ReviewFrontiers in cellular neuroscience2024
The impact of COVID-19 on accelerating of immunosenescence and brain aging.
Review in Frontiers in cellular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Review
- Translational insights into Long-COVID: evaluation of preclinical animal models along the lung-brain-immune axis with focus on Golden Syrian Hamsters.Journal of neuroinflammation · 2026Review
- Shared genetic structure between COVID-19 and migraine: insights from large-scale genome-wide cross-trait analysis.Virus research · 2026Article
- Persistent Interleukin-1β Elevation in Post-COVID-19 Patients: Findings From a Nationwide Registry Study in Japan.Neuropsychopharmacology reports · 2026Article
- Endothelial Biomarkers and Cytokine Profiles: Signatures of Mortality in Severe COVID-19.International journal of molecular sciences · 2026Observational
- Respiratory and Pleural Pathogens in Octogenarians Hospitalized with COVID-19: Impact of Secondary Bacterial Pneumonia on Day-5 SOFA and Mortality.Microorganisms · 2026Article
- The inflammation-immunosuppression loop as a driver of immune dysfunction and secondary infections in severe COVID-19.Frontiers in immunology · 2026Review
- Host-virus resilience networks and viral inflammaging circuits in aging and long COVID: a CMV-centered perspective.Frontiers in cellular and infection microbiology · 2026Review
- Post-COVID varicella-zoster virus reactivation: lowering the immunological threshold for latency breakdown.Frontiers in cellular and infection microbiology · 2026Review
- From HIV to SARS-CoV-2 associated neurological disorder ("HAND" to "SAND"): Viral infection as a "time-bomb" for the aging brain.Neuroscience applied · 2026Review
- A Multicentric Study on Adverse COVID-19 Outcomes Among Pregnant and Nonpregnant Women in Multidisciplinary Hospitals of Kazakhstan.Diagnostics (Basel, Switzerland) · 2025Article
- Long COVID: a long road ahead.Oxford open immunology · 2025Article
- Neuroimmune dynamics and brain aging: mechanisms and consequences.Frontiers in aging neuroscience · 2025Review
- Long-term neurocognitive outcomes of SARS-CoV-2 infection in a hamster model.Frontiers in microbiology · 2025Article
- A Clinical Risk Score Based on Albumin and Electrolyte Levels for Predicting Death Risk in Hospitalized Elderly COVID-19 Patients.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has profoundly impacted global health, affecting not only the immediate morbidity and mortality rates but also long-term health outcomes across various populations. Although the acute effects of COVID-19 on the respiratory system have initially been the primary focus, it is increasingly evident that the virus can have significant impacts on multiple physiological systems, including the nervous and immune systems. The pandemic has highlighted the complex interplay between viral infection, immune aging, and brain health, that can potentially accelerate neuroimmune aging and contribute to the persistence of long COVID conditions. By inducing chronic inflammation, immunosenescence, and neuroinflammation, COVID-19 may exacerbate the processes of neuroimmune aging, leading to increased risks of cognitive decline, neurodegenerative diseases, and impaired immune function. Key factors include chronic immune dysregulation, oxidative stress, neuroinflammation, and the disruption of cellular processes. These overlapping mechanisms between aging and COVID-19 illustrate how the virus can induce and accelerate aging-related processes, leading to an increased risk of neurodegenerative diseases and other age-related conditions. This mini-review examines key features and possible mechanisms of COVID-19-induced neuroimmune aging that may contribute to the persistence and severity of long COVID. Understanding these interactions is crucial for developing effective interventions. Anti-inflammatory therapies, neuroprotective agents, immunomodulatory treatments, and lifestyle interventions all hold potential for mitigating the long-term effects of the virus. By addressing these challenges, we can improve health outcomes and quality of life for millions affected by the pandemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.